To include your compound in the COVID-19 Resource Center, submit it here.

Incyte gains rights to Macrogenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012. MacroGenics retains rights to develop combinations that include the

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE